common.study.topics.clinical

Breast Cancer Response Evaluation for Individualized Therapy

common.study.values.description

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY

The current study (BREVITY) aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies at ~2-3 weeks after the initiation of neoadjuvant chemotherapy.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Recruiting patients only common.study.methods.is-healthy-yes

Procedure - Core needle biopsy

1st core needle biopsy for RDA 2 specimens: Time Point: ~2-3 weeks after initiation of 1st cycle of chemotherapy; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin. 2nd core needle biopsy for RDA: Time Point: if therapy is changed (as part of SoC), a second biopsy ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 da ...read more on ClinicalTrials.org

participant.views.study.view.additional

participant.views.study.view.scientific-title

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)

common.study.values.clinical-trial-id

NCT03524430

participant.views.study.view.id

wdLNDa